Nicole Germino
Stock Analyst at Truist Securities
(4.59)
# 234
Out of 4,980 analysts
25
Total ratings
63.64%
Success rate
30.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $126 → $139 | $144.99 | -4.13% | 9 | Aug 14, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $18 → $14 | $8.60 | +62.79% | 3 | May 14, 2025 | |
| CATX Perspective Therapeutics | Maintains: Buy | $10 → $8 | $3.36 | +138.45% | 3 | May 14, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.51 | +883.86% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $22.28 | +7.72% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $10.49 | - | 2 | Sep 3, 2021 |
Insmed
Aug 14, 2025
Maintains: Buy
Price Target: $126 → $139
Current: $144.99
Upside: -4.13%
Y-mAbs Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $8.60
Upside: +62.79%
Perspective Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.36
Upside: +138.45%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.51
Upside: +883.86%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $22.28
Upside: +7.72%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $10.49
Upside: -